China’s Synovac Kovid Vaccine 78% Brazil Trial, Effective in Folha Report

Photographer: Jonne Roriz / Bloomberg

Vaccine developed by china Synovac Biotech Ltd was found to be 78% effective against Kovid-19 in late-stage trials in Brazil, with the most definitive evidence on the efficacy of the shot following previous data causing doubt and confusion.

The safety rate, confirmed by São Paulo state officials, was derived from Synovac’s most advanced last-stage trials in Brazil involving approximately 13,000 participants. Coming after The data was withheld in a progress update in late December, with rates still lower than the 95% effectiveness seen in state-of-the-art mRNA vaccines developed by Pfizer Inc. and Modern Inc. and being deployed in the US.

Synovac’s Coronavac vaccine was 78% effective in preventing mild cases of Kovid-19 and 100% against severe and moderate infections, Butanon Institute director Dimas Kovas said partnering with Synovac to produce the shot locally Of. The trial saw about 220 participants infected – 160 in the placebo group while about 60 received the vaccine, Kovas said.

While the latest revelations clearly indicate the efficacy of the vaccine, it was not the complete picture. It was unclear how the Brazilian researchers calculated the efficacy rate, as officials did not provide a more detailed breakdown of the study – which included information about age groups and side effects of the shot. He also did not specify when the full document would be published.

The Butanon Institute further declined, saying that it had no information before releasing it at Thursday’s press conference. Beijing-based Synovac did not immediately respond to calls and text messages.

Synovac Biotech's Coronavirus Vaccine Arrives in Brazil

Director of the Buxton Institute, Dimas Tedu Kovas, Health Secretary of Sao Paulo, Jean Gorinchitine, and João Doria, Governor of São Paulo, hold the boxes of the Synovac Biotech – Coronavirus vaccine at Guarulhos International Airport in Sao Paulo, Brazil. 19 November 2020.

Photographer: Jonne Roriz / Bloomberg

Chinese vaccine developers’ lack of timely and clear disclosures has contributed to a lack of confidence in their shots. Conflicting and incomplete information from Synovac’s tests last month led to confusion over how effective Coronavac is in protecting people against the development of Kovid-19.

After Brazil, Turkey results revealed the efficacy of China shot

Nevertheless, the latest results indicate that Synovac’s vaccine provides significant protection against Kovid-19, which could rely on shot supply deals in countries such as Indonesia and Brazil. Kovanus said the Butanton Institute planned to request an emergency use authority from the Brazilian regulator.

China is trying to increase its geopolitical influence through vaccine diplomacy, and the revelations on the Synovac shot add another vaccine to its arsenal.

While less effective than Pfizer and Modern’s vaccines, Coronavac roughly corresponds to a 79.3% efficacy rate for a state-owned developer Kovid vaccine of National Biotech Group Company of China. Another shot by AstraZeneca PLC has shown mixed results – it was 90% effective when one half dose was given before a full-dose booster, while two full doses showed an efficacy of 62%.

Fridge temperature

Synovac and CNBG vaccines use the inactive version of coronavirus to stimulate the body’s immune response. They can be stored at refrigerator temperatures, making them potentially better options for distribution and use in the developing world than mRNA vaccines that require deep freezing.

Over 15.9 million shots given: Kovid-19 Vaccine Tracker

China is already More than 4.5 million doses of its home grown vaccines were administered under the Emergency Use Authority granted in the middle of last year, and is Goals for Vaccination of 50 million people against the virus before the annual Lunar New Year holiday in early February. Last week’s shot of CNBG approved for first use General public in China.

Synovac can make more than 600 million doses a year at its production facilities in China. The company has orders from countries where it is conducting vaccine trials, including Brazil, Turkey and Indonesia, and will also supply to Singapore and Hong Kong in addition to the Chinese mainland.

Misleading data


Leave a Reply

Your email address will not be published.